NCT05533697 2026-02-06
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2 Recruiting
ModernaTX, Inc.
Bristol-Myers Squibb
Anaveon AG
SQZ Biotechnologies